Uncategorized
Eleven Biotherapeutics initiates phase 2 trial of allergic conjunctivitis treatment
Eleven Biotherapeutics has begun patient dosing in its phase 2 clinical trial of EBI-005 for the treatment of allergic conjunctivitis, according to a press release. EBI-005, generated using the company’s AMP-Rx platform, is designed to bind and block the interleukin-1 receptor to the point of preventing transmission of biological signals responsible for signs and symptoms of ocular surface diseases, the release said.